Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Placebo-Controlled Phase Ⅱ Study to Evaluate the Efficacy of Adjunctive Everolimus Treatment in Patients With Refractory Epilepsy

NCT05613166 is registered in ClinicalTrials.gov with National Institute on Drug Dependence, China as lead sponsor.

NCT NCT05613166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Placebo-Controlled Phase Ⅱ Study to Evaluate the Efficacy of Adjunctive Everolimus Treatment in Patients With Refractory Epilepsy
Lead sponsor
National Institute on Drug Dependence, China
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2022
Completion date
March 31, 2023
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy